Business, energy, technology, markets and global industry news from Business News Today

Accord BioPharma

PharmaDeviceNews Accord BioPharma
Sail Biomedicines’ in vivo CAR-T collaboration with Johnson & Johnson highlights growing investment in RNA-based immune-cell therapies for autoimmune diseases. Representative image.
Pharma & Biotech

Bio-Thera’s BAT2506 wins a China first, but can it challenge Johnson & Johnson’s Simponi?

Bio-Thera wins China's first golimumab biosimilar approval for BAT2506, opening a new market while pricing and competition remain critical.

Read More
Representative image showing a prostate cancer research and testing environment, aligned with our coverage of Rubraca’s FDA approval and its Phase 3 TRITON3 trial results in BRCA-mutated metastatic castration-resistant prostate cancer.
Pharma & Biotech

China approves Foresee’s twice-yearly prostate cancer injection. Could it unlock a $123.85m milestone deal?

Foresee's CAMCEVI 42 mg wins China approval for advanced prostate cancer. Examine GeneScience's launch plans, clinical evidence and licensing economics.

Read More
Accord BioPharma’s U.S. launch of Osvyrti and Jubereq brings two interchangeable denosumab biosimilars into the increasingly competitive osteoporosis and oncology-support market. Representative image.
Pharma & Biotech

Jubereq launch: Accord BioPharma challenges Xgeva in cancer-related bone complications

Accord BioPharma launches Osvyrti and Jubereq as interchangeable denosumab biosimilars, testing price, payer access and provider adoption.

Read More